DEFA14A: CONMED Addresses Stockholder Concerns Over Dilution in 2025 Long-Term Incentive Plan

CONMED provides additional details on its equity strategy, emphasizing its reliance on stock options and adjusted dilution levels, to garner support for the 2025 Long-Term Incentive Plan.

Summary

• CONMED is seeking stockholder approval for the 2025 Long-Term Incentive Plan at the upcoming Annual Stockholders Meeting on May 20, 2025.
• The company is providing additional information regarding its equity strategy to address concerns about share usage and dilution.
• CONMED's long-term incentive program relies heavily on stock options compared to peers who use more Restricted Share Units (RSUs).
• The company's total dilution levels appear elevated due to the emphasis on stock options and the fact that many options remain unexercised.
• However, when considering only unvested options, CONMED's adjusted dilution is 12.3%, which compares favorably to the industry average of 14.4%.
• CONMED's three-year average gross unadjusted burn rate of approximately 2.5% is below the industry average of 3.79%.
• The company is requesting an increase of 3.6 million shares for issuance under the plan, which is expected to cover approximately three years of equity grant needs.
• CONMED encourages stockholders to vote in favor of the 2025 Long Term Incentive Plan.
• The company is open to discussing its equity strategy with stockholders and welcomes feedback.

Sentiment

Score: 7

Explanation: The document presents a balanced view, acknowledging concerns about dilution but highlighting positive aspects of CONMED's equity strategy and performance relative to industry peers. The tone is proactive and reassuring.

Positives

• CONMED's adjusted dilution level of 12.3% is better than the industry average of 14.4%.
• The company's three-year average gross unadjusted burn rate of 2.5% is lower than the industry average of 3.79%, indicating prudent equity deployment.
• The requested increase of 3.6 million shares is intended to cover three years of equity grant needs, allowing for regular stockholder input.
• CONMED is committed to aligning executive compensation with stockholder interests.

Negatives

• CONMED's total dilution levels are elevated due to the emphasis on stock options and the fact that many options remain unexercised.

Risks

• If stockholders do not approve the 2025 Long-Term Incentive Plan, CONMED may face challenges in attracting and retaining key employees.
• Continued reliance on stock options could lead to higher dilution levels if employees exercise their options in the future.
• Industry averages may not be directly comparable due to differences in company size, growth stage, and business model.

Future Outlook

CONMED expects the requested 3.6 million share increase to satisfy approximately three years of equity grant needs.

Management Comments

• We are sensitive to the dilutive impact our equity usage has on our stockholders; however, we believe stock options align participants with long-term absolute stockholder returns.
• We have been and will continue to be responsible in our equity usage.

Industry Context

The document positions CONMED's equity strategy relative to its peers, highlighting differences in the use of stock options versus RSUs and comparing dilution and burn rates to industry averages.

Comparison to Industry Standards

• CONMED compares its adjusted dilution of 12.3% favorably to the industry average of 14.4%.
• CONMED's three-year average gross unadjusted burn rate of 2.5% is lower than the industry average of 3.79%.
• The document does not mention specific comparable companies, but it implies that CONMED's peers rely more heavily on RSUs than stock options.

Stakeholder Impact

• Approval of the 2025 Long-Term Incentive Plan is intended to benefit stockholders by aligning executive compensation with long-term returns.
• The plan is also intended to benefit employees by providing them with equity-based incentives.

Next Steps

• Stockholders will vote on the 2025 Long-Term Incentive Plan at the Annual Stockholders Meeting on May 20, 2025.
• Stockholders are encouraged to contact CONMED with any questions or feedback regarding the company's equity strategy.

Key Dates

Keywords

Long-Term Incentive Plan, Equity Strategy, Stock Options, Dilution, Burn Rate, CONMED, Compensation, Stockholders